Kodiak Sciences Inc. KOD
At closeNov 3, 2026, 4:06 PM EST
After hours · Nov 3, 4:06 PM ET
- YTD
- +253.68%
- 1 year
- +432.81%
- Market cap
- 6.22B
- EPS (ttm)
- -4.19
- Shares out
- 62.85M
- Forward P/E
- -28.78
- YTD return
- +253.68%
- 1-year return
- +432.81%
- Volume
- 803.26K
- Avg volume
- 1.71M
- Open
- 98.76
- Previous close
- 97.63
- Day's range
- 97.80 – 102.04
- 52-week range
- 15.83 – 104.00
- Beta
- 1.98
- Analysts
- Strong Buy
- Price target
- 121.67 (+23.0%)
- Earnings date
- Nov 12, 2026
YTD +72.87 (+280.05%)
Key statistics
- Enterprise value
- 6.05B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 101.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -58.39M
- Total cash
- 125.90M
- Total debt
- 52.76M
- Return on equity
- -368.37%
- Short % of float
- 21.40%
- 50-day average
- 64.91
- 200-day average
- 42.45
Analyst view
Consensus: strong buy
- Target (low)
- 103.00
- Target (mean)
- 121.67
- Target (high)
- 145.00
- Strong buy1
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -1.01.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -1.06 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.95647 | -1.05 | -0.09 | -9.78% |
| May 7, 2026 | Mar 31, 2026 | -0.93 | -0.94 | -0.01 | -1.08% |
| Mar 31, 2026 | Dec 31, 2025 | -1.02 | -1.04 | -0.02 | -1.96% |
| Nov 13, 2025 | Sep 30, 2025 | -1.07 | -1.16 | -0.09 | -8.41% |
| Aug 13, 2025 | Jun 30, 2025 | -1.01 | -1.03 | -0.02 | -1.98% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 28, 2026 | LifeSci Capital | main | Outperform | Outperform |
| Sep 28, 2026 | UBS | main | Buy | Buy |
| Sep 28, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 17, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kodiak.com
News
10 Health Care Stocks Whale Activity In Today’s Session 
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher? 
Kodiak Sciences Inc. (NASDAQ:KOD) Stock Has Average Target Price of $104.71 
11 Stocks Most Likely to See a Short Squeeze Rally 
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $126 
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026 
Top 3 Health Care Stocks That May Collapse In Q4 
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study 
Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Acquires 33,726 Shares of Company Stock 
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
Your note
Sign in to keep a note on KOD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 28, 2026 | 0 |
| BORGESON JOHN A | Chief Financial Officer | Sale | Jun 3, 2026 | 211,930 |
| PERLROTH VICTOR D | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 24, 2026 | 3,676,060 |
| YANG TAIYIN | Director | Conversion of Exercise of derivative security | Oct 22, 2026 | 20,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 31.69% | 19,919,186 | 1.97B | Jun 29, 2026 |
| Blackrock Inc. | 6.58% | 4,135,355 | 408.95M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.17% | 3,248,611 | 321.26M | Jun 29, 2026 |
| State Street Corporation | 3.85% | 2,419,417 | 239.26M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 3.69% | 2,316,014 | 229.03M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.87% | 1,804,632 | 178.46M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.05% | 1,288,755 | 127.44M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.04% | 1,281,918 | 126.77M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.63% | 1,024,195 | 101.28M | Sep 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.61% | 1,013,711 | 100.25M | Jun 29, 2026 |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 0.95% | 595,991 | 58.94M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.94% | 590,816 | 58.43M | Jun 29, 2026 |